← All trials
NCT04641819
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2020
- Primary completion
- Feb 28, 2022
- Completion date
- May 31, 2022
- First posted
- Nov 24, 2020
- Last posted
- Nov 25, 2020
- Enrollment
- 1525
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shanghai University of Traditional Chinese MedicineLead sponsor
- Shanghai University of Traditional Chinese MedicineReponsible party - principal investigator
- LinkDoc Technology (Beijing) Co. Ltd.Collaborator
- Shaanxi Buchang Pharmaceutical Co., LtdCollaborator
- Shanghai University of Traditional Chinese MedicineOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.